Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis

Ross L. Levine(Memorial Sloan Kettering Cancer Center), D. Gary Gilliland(Brigham and Women's Hospital), Stefan Fröhling(German Cancer Research Center), Ayalew Tefferi(Mayo Clinic), Titus J. Boggon(Yale Cancer Center), Thomas Mercher(Inserm), Brian J.P. Huntly(Wellcome/MRC Cambridge Stem Cell Institute), Stephanie J. Lee(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Ruben A. Mesa(Atrium Health Wake Forest Baptist), James D. Griffin(Harvard University), Michael J. Eck(Harvard University), Alan D. D’Andrea(Dana-Farber Cancer Institute), Gerlinde Wernig(Stanford University), Todd R. Golub(Broad Institute), Jeffrey C. Lee(Broad Institute), Sumin Koo(Brigham and Women's Hospital), Konstanze Döhner(University Hospital Ulm), Sandra Moore(Brigham and Women's Hospital), Matthew Meyerson(Broad Institute), William R. Sellers(Broad Institute), Jan Cools(KU Leuven), Stacey Gabriel(Broad Institute), Jennifer Adelsperger(Brigham and Women's Hospital), Benjamin L. Ebert(Dana-Farber Cancer Institute), Peter Vandenberghe(KU Leuven), Iwona Włodarska(KU Leuven), Peter Marynen(Vlaams Instituut voor Biotechnologie), Martha Wadleigh(Dana-Farber Cancer Institute), Jennifer Clark(Boston Children's Hospital)
Cancer Cell
April 1, 2005
Cited by 2,991


Related Papers